How Cardiac Myosin Inhibitors Work
Cardiac myosin inhibitors like mavacamten and aficamten work by allosterically and reversibly inhibiting cardiac myosin motor activity, reducing the number of myosin heads that can form force-generating cross-bridges with actin, thereby decreasing cardiac contractility and left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. 1, 2
Molecular Mechanism of Action
Cardiac myosin inhibitors target the fundamental pathophysiology of HCM at the sarcomere level:
Mavacamten modulates the number of myosin heads that can enter "on actin" (power-generating) states, reducing the probability of both force-producing (systolic) and residual (diastolic) cross-bridge formation. It shifts the overall myosin population toward an energy-sparing, recruitable, super-relaxed state 1.
Aficamten reduces the force generated by myosin at the cardiac sarcomere by strongly slowing phosphate release and stabilizing a weak actin-binding state. It prevents the conformational changes necessary for myosin to enter the strongly actin-bound force-generating state 2, 3.
Key Mechanistic Differences
While both drugs inhibit myosin, their structural effects differ:
Mavacamten structurally sequesters myosin heads along the thick filament and affects both myosin structure and ATPase activity 4.
Aficamten does not structurally sequester myosin heads along the thick filament. Instead, it inhibits ATPase activity by shifting myosin heads from higher to slower ATPase states, with emergence of a super-slow biochemical nucleotide turnover state, without appreciably altering myosin structure 5, 4.
Clinical Effects in HCM Patients
The myosin inhibition translates to several measurable clinical effects:
Hemodynamic Improvements
Reduces LVOT gradients: Both drugs substantially decrease resting and provoked (Valsalva) left ventricular outflow tract gradients, with effects observable within 2-4 weeks 1, 2.
Improves cardiac filling pressures: By reducing hypercontractility and excessive cross-bridge formation 1.
Cardiac Remodeling
Reduces left ventricular mass index (LVMI): Mavacamten showed mean reduction of -7.4 g/m² versus increase of 8.9 g/m² with placebo 1.
Decreases left atrial volume index (LAVI): Indicating improved diastolic function 1, 2.
Reduces cardiac biomarkers: Both drugs substantially lower NT-proBNP (a marker of cardiac wall stress) and troponin I 1, 2.
Critical Safety Consideration: Effect on LVEF
Both drugs reduce left ventricular ejection fraction as an expected pharmacodynamic effect of decreased contractility. This is not a side effect but rather the intended mechanism of action 6, 7.
The 2024 AHA/ACC HCM Guidelines mandate that cardiac myosin inhibitors must be discontinued if LVEF falls below 50%, regardless of symptoms 6, 7.
LVEF reductions are generally within the normal range during treatment 1.
After discontinuation, LVEF returns to baseline within 4-8 weeks 1, 2.
Reversibility and Kinetics
A critical feature distinguishing these drugs from traditional negative inotropes:
LVEF and LVOT gradients return to baseline within 4-8 weeks after stopping treatment 1, 2.
This reversibility reflects the allosteric, non-covalent binding mechanism 1, 2.
Clinical Context
These drugs represent the first disease-modifying therapy for HCM, targeting the underlying sarcomere hypercontractility rather than merely providing symptomatic palliation like beta-blockers or calcium channel blockers 8, 9. The 2024 AHA/ACC Guidelines now recommend myosin inhibitors as first-line options for symptomatic obstructive HCM patients 7.